EGFR and cancer: Some patients initially respond to tyrosine kinase inhibitors (TKI) but ultimately develop resistance: cancers acquire TKI-desensitizing EGFR mutations or activate compensatory signals, including WNT/β-catenin, the mechanistic target of rapamycin mTOR, and AKT signaling to drive cancer recurrence12–20.